Synonyms: compound 4 [WO2019218987A1] [2] | D-0316 | D0316 | Surmana®
befotertinib is an approved drug (China NMPA (2023))
Compound class:
Synthetic organic
Comment: Befotertinib (D-0316) is an third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that was developed as a treatment for non-small cell lung cancer (NSCLC) [2].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (China NMPA (2023)) |
IUPAC Name ![]() |
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-[1-(2,2,2-trifluoroethyl)indol-3-yl]pyrimidin-2-yl]amino]phenyl]prop-2-enamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
11357 | befotertinib |
Synonyms ![]() |
|
compound 4 [WO2019218987A1] [2] | D-0316 | D0316 | Surmana® |
Database Links ![]() |
|
CAS Registry No. | 1835667-63-4 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL5095167 |
GtoPdb PubChem SID | 485206072 |
PubChem CID | 130412842 |
Search Google for chemical match using the InChIKey | USOCZVZOXKTJTI-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | USOCZVZOXKTJTI |
Search PubMed clinical trials | befotertinib |
Search PubMed titles | befotertinib |
Search PubMed titles/abstracts | befotertinib |
UniChem Compound Search for chemical match using the InChIKey | USOCZVZOXKTJTI-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | USOCZVZOXKTJTI-UHFFFAOYSA-N |